Treatment of ADHD

An indole, acetyl-based technology used in the treatment of ADHD to address irritability, spasticity and depressive symptoms

Inactive Publication Date: 2004-06-23
H LUNDBECK AS
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, adverse effects such as insomnia, decreased appetite, irritability, seizures, and depressive symptoms are more common in ADHD patients treated with psychostimulants after long-term treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of ADHD
  • Treatment of ADHD
  • Treatment of ADHD

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0014] Compound 3-[1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl ]-6-Chloro-1H-indole and its enantiomers were first disclosed in WO98 / 28293. The application also contains evidence that the compound is a potent dopamine D 4 Ligand data.

[0015] The present invention includes the use of the racemate and each enantiomer of the compound of formula (I) for the treatment of attention deficit hyperactivity disorder.

[0016] Compounds of formula (I) and their enantiomers and pharmaceutically acceptable salts can be prepared as described in WO98 / 28293, see in particular Examples 20 and 34.

[0017] The compound --(S)-(+)-3-[1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)B base]-1,2,3,6-tetrahydropyridin-4-yl]-6-chloro-1H-indole was tested in which said DAT-KO mice are a kind of Animal models of individual-like behavior and responses to psychostimulants (Gainetdinov et al., Science 1999, 283, 397-401). The compound was found to be effective in this mod...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The use of 3-[1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)ethyl]-1,2,3,6-tetr ahydropyridin-4-yl]-6-chloro-1H-indole, any of its enantiomers and pharmaceutically acceptable salts thereof for the preparation of a pharmaceutical composition for the treatment of attention deficit hyperactivity disorder.

Description

[0001] The present invention relates to 3-[1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)ethyl]-1,2,3,6-tetrahydropyridine-4 -Base]-6-chloro-1H-indole, its enantiomer and its pharmaceutically acceptable salt are used for the preparation of the application of the medicine for the treatment of ADHD (attention deficit hyperactivity disorder). Background technique [0002] ADHD clinically refers to a relatively common syndrome (epidemiological statistics have shown that the incidence of ADHD in the general population is 2-10%). ADHD begins in childhood and generally regresses in adulthood (Szatmari Child Adolesc. Psychiat. Clin. North Am. 1982, 1, 361-371). ADHD is clinically characterized by inattention (eg, inability to pay close attention, difficulty maintaining attention, difficulty organizing tasks and activities, and being easily distracted by external stimuli), hyperactivity (eg, difficulty staying seated, moving in inappropriate situations Hyperactivity, where the patient appe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/44A61K31/4439A61P25/00C07D401/14A61P25/14
CPCA61K31/4439A61K31/44A61P25/00A61P25/14
Inventor K·P·赫尔特尔J·阿恩特
Owner H LUNDBECK AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap